Uterine Cancer pp 247-257 | Cite as

Management of Uterine Sarcomas

  • Leslie R. BoydEmail author
Part of the Current Clinical Oncology book series (CCO)


Uterine sarcomas, including the subtypes leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma, are a heterogenous group of tumors which vary widely in their biology and prognosis. Surgery is the mainstay of treatment. The roles of chemotherapy, radiation therapy and hormonal therapy are poorly defined, in large part due to the rarity of these tumors. Prior clinical trials grouped uterine sarcomas together, which helped trial accrual but hampered applicability of trial results. Today’s trials are specific to each histology, and are often supplemented by molecular studies to improve interpretation of results. Continued investigations should point the way for future therapies directed towards these tumors.


Adenosarcoma Endometrial stromal sarcoma Gemcitabine Docetaxel Hormonal therapy Leiomyosarcoma Undifferentiated endometrial sarcoma Uterine sarcomas 


  1. 1.
    Siegel R, et al. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956–1992: incidence, survival and mortality. Eur J Cancer. 1997;33(6):907–11.PubMedGoogle Scholar
  3. 3.
    Koivisto-Korander R, et al. Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases. Maturitas. 2012;72:56–60.PubMedGoogle Scholar
  4. 4.
    Felix AS, et al. The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer. 2013;108:727–34.PubMedPubMedCentralGoogle Scholar
  5. 5.
    FIGO Committee on Gynecologic Oncology. FIGO staging for uterine sarcomas. Int J Gynecol Obstet. 2009;104:179.Google Scholar
  6. 6.
    Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89:460–9.PubMedGoogle Scholar
  7. 7.
    Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88:2782–6.PubMedGoogle Scholar
  8. 8.
    Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol. 1994;83(3):414–8.PubMedGoogle Scholar
  9. 9.
    Goff BA, Rice LW, Fleischhacker D, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol Oncol. 1993;50:105–9.PubMedGoogle Scholar
  10. 10.
    Kapp DS, et al. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112:820–30.PubMedGoogle Scholar
  11. 11.
    George S, et al. Retrospective cohort study evaluating the impact of intraperitoneal morcellation of outcomes of localized uterine leiomyosarcoma. Cancer. 2014;120:3154–8.PubMedGoogle Scholar
  12. 12.
    Park JY, et al. The impact of tumor morcellation during surgery on the prognosis of patients with apparent early uterine leiomyosarcoma. Gynecol Oncol. 2011;122:255–9.PubMedGoogle Scholar
  13. 13.
    Morice P, et al. Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. Eur J Gynaecol Oncol. 2003;24:237–40.PubMedGoogle Scholar
  14. 14.
    Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JLJR. Treatment of uterine leiomyosarcoma. Obstet Gynecol. 1988;71:845–50.PubMedGoogle Scholar
  15. 15.
    Koontz JI, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. PNAS. 2001;98:6348–53.PubMedGoogle Scholar
  16. 16.
    Micci F. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genese JAZF1/PHF1 and EPC/PHF1 in endometrial stromal sarcoma. Cancer Res. 2006;66:107–12.PubMedGoogle Scholar
  17. 17.
    Chiang S, et al. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol. 2011;35(9):1364–72.PubMedGoogle Scholar
  18. 18.
    Signorelli M, et al. Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review. Int J of Gynecol. Cancer. 2010;20(8):1363–6.Google Scholar
  19. 19.
    Barney B, et al. Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer. 2009;19(7):1232–8.PubMedGoogle Scholar
  20. 20.
    Yoon A, et al. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: a multicenter review of 114 cases. Gynecol Oncol. 2014;132:70–5.PubMedGoogle Scholar
  21. 21.
    Feng W, et al. Stage I to II WHO-2003 defined low-grade endometrial stromal sarcoma: how much primary therapy is needed and how little is enough? Int J Gynecol Cancer. 2013;23(3):488–93.PubMedGoogle Scholar
  22. 22.
    Shah JP, et al. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol. 2008;112:1102–8.PubMedGoogle Scholar
  23. 23.
    Chan JK, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99:1210–5.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Arend R, et al. Long-term outcome and natural history of uterine adenosarcomas. Gynecol Oncol. 2010;119:305–8.PubMedGoogle Scholar
  25. 25.
    Bernard B e. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival. Gynecol Oncol. 2013;131:634–9.PubMedGoogle Scholar
  26. 26.
    Tanner EJ, et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol. 2013;129:140–4.PubMedGoogle Scholar
  27. 27.
    Piscuoglio S, et al. Uterine adenosarcomas are mesenchymal neoplasms. J Pathol. 2016;238:381–8.PubMedGoogle Scholar
  28. 28.
    Soslow R, et al. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol. 2008;32(7):1013–21.PubMedGoogle Scholar
  29. 29.
    Michener C, Simon NL. Ovarian conservation in a woman of reproductive age with mullerian adenosarcoma. Gynecol Oncol. 2001;83:424–7.PubMedGoogle Scholar
  30. 30.
    Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702–9.PubMedGoogle Scholar
  31. 31.
    Ferrer F, Sabater S, Farrus B, et al. Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys. 1999;44:47–52.PubMedGoogle Scholar
  32. 32.
    Sampath S, et al. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys. 2010;76(3):728–34.PubMedGoogle Scholar
  33. 33.
    Magnuson WJ, et al. Impact of adjuvant pelvic radiotherapy in stage I uterine sarcoma. Anticancer Res. 2015;35(1):365–70.PubMedGoogle Scholar
  34. 34.
    Mahdavi A, et al. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: A 20 year experience. Int J Gynecol Cancer. 2009;19:1080–4.PubMedGoogle Scholar
  35. 35.
    Reed NS, et al. Phase III randomized study to evaluate the role of adjuvant pelvic in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44:808–18.PubMedGoogle Scholar
  36. 36.
    Wright JD, et al. The role of radiation in improving survival for early stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199:536.e1–8.Google Scholar
  37. 37.
    Weitmann HD, Knocke TH, Kucera H, Potter R. Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys. 2001;49(3):739–48.PubMedGoogle Scholar
  38. 38.
    Ricci S, et al. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? Gynecol Oncol. 2013;131:629–33.PubMedGoogle Scholar
  39. 39.
    Mancari R, et al. Adjuvant chemotherapy in stage I – II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients. Gynecol Oncol. 2014;133:531–6.PubMedGoogle Scholar
  40. 40.
    Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1240–5.PubMedGoogle Scholar
  41. 41.
    Peters WA 3rd, Rivkin SE, Smith MR, Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors. Gynecol Oncol. 1989;34:323–7.PubMedGoogle Scholar
  42. 42.
    Kushner DM, Webster KD, Belinson JL, Rybicki LA, Kennedy AW, Markman M. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynecol Oncol. 2000;78:221–7.PubMedGoogle Scholar
  43. 43.
    van Nagell JR Jr, Hanson MB, Donaldson ES, Gallion HH. Adjuvant vincristine, dactinomycin, and cyclophosphamide therapy in stage I uterine sarcomas. A pilot study. Cancer. 1986;57:1451–4.PubMedGoogle Scholar
  44. 44.
    Hannigan EV, Freedman RS, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with adriamycin. Gynecol Oncol. 1983;16:101–4.PubMedGoogle Scholar
  45. 45.
    Hannigan EV, Freedman RS, Elder KW, Rutledge FN. Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide. Gynecol Oncol. 1983;15:224–9.PubMedGoogle Scholar
  46. 46.
    Pautier P, Rey A, Haie-Meder C, et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int J Gynecol Cancer. 2004;14:1112–7.PubMedGoogle Scholar
  47. 47.
    Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a Phase II Trial. J Clin Oncol. 2002;20:2824–31.PubMedGoogle Scholar
  48. 48.
    Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329–34.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Hensley ML, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013;119:1555–61.PubMedGoogle Scholar
  50. 50.
    Chu MC, Mor G, Lim C, Zheng W, Parkash V, Schwartz PE. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003;90:170–6.PubMedGoogle Scholar
  51. 51.
    Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol. 1990;39:364–7.PubMedGoogle Scholar
  52. 52.
    Thanopoulou E, et al. Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital. Clin Sarcoma Res. 2015;5:8.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Mizuno M, et al. Long-term medroxyprogesterone acetate therapy for low-grade endometrial stromal sarcoma. Int J Clin Oncol. 2012;17:348–54.PubMedGoogle Scholar
  54. 54.
    Spano JP, Soria JC, Kambouchner M, et al. Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol. 2003;20:87–93.PubMedGoogle Scholar
  55. 55.
    Maluf FC, Sabbatini P, Schwartz L, Xia J, Aghajanian C. Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol. 2001;82:384–8.PubMedGoogle Scholar
  56. 56.
    Leunen M, Breugelmans M, De Sutter P, et al. Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol. 2004;95:769.PubMedGoogle Scholar
  57. 57.
    Mesia AF, Demopoulos RI. Effects of leuprolide acetate on low-grade endometrial stromal sarcoma. Am J Obstet Gynecol. 2000;182:1140–1.PubMedGoogle Scholar
  58. 58.
    Burt BM, et al. Repeated and aggressive pulmonary resections for leiomyosarcoma metastases extends survival. Ann Thorac Surg. 2011;92:1202–7.PubMedGoogle Scholar
  59. 59.
    Clavero JM. Gynecologic cancers: factors affecting survival after pulmonary metastasectomy. Ann Thorac Surg. 2006;81:2004–7.PubMedGoogle Scholar
  60. 60.
    Giuntoli R, et al. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol. 2007;106:82–8.PubMedGoogle Scholar
  61. 61.
    Leitao MM, et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002;87:287–94.PubMedGoogle Scholar
  62. 62.
    Leitao MM, et al. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol. 2012;125:409–13.PubMedGoogle Scholar
  63. 63.
    Spanos W, Guse C, Perez C, Grisby P, Doggett RL, Poulter C. Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: preliminary report of RTOG 8502. Int J Radiat Oncol Biol Phys. 1989;17:659–61.PubMedGoogle Scholar
  64. 64.
    Spanos WJ, et al. Late effect of multiple daily fraction palliation schedule for advanced pelvic malignancies (RTOG 8502). Int J Radiat Oncol Biol Phys. 1994;29(5):961–7.PubMedGoogle Scholar
  65. 65.
    Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983;52:626–32.Google Scholar
  66. 66.
    Muss HB, Bundy B, DiSaia PJ, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a Phase III trial of the Gynecologic Oncology Group). Cancer. 1985;55:1648–53.PubMedGoogle Scholar
  67. 67.
    Loehrer PJ, Sledge GW, Nicaise C, et al. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol. 1989;7:1655–9.PubMedGoogle Scholar
  68. 68.
    Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276–85.PubMedGoogle Scholar
  69. 69.
    Currie J, Blessing JA, Muss HB, Fowler J, Berman M, Burke TW. Combination chemotherapy with hydroxyurea, dacarbazine (DTIC), and etoposide in the treatment of uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1996;61:27–30.PubMedGoogle Scholar
  70. 70.
    Piver MS, DeEulis TG, Lele SB, Barlow JJ. Cyclophosphamide, vincristine, adriamycin and dimethyl-triazeno imidazole carboxamide (CYVADIC) for sarcomas of the female genital track. Gynecol Oncol. 1982;14:319–23.PubMedGoogle Scholar
  71. 71.
    Pautier P, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS- 02): a non-randomised, multicenter, phase 2 trial. Lancet Oncol. 2015;16:457–64.PubMedGoogle Scholar
  72. 72.
    Hensley ML, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first line treatment for metastatic uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 33:1180–5.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Pautier P et al. Randomized multicenter and stratified phase II study of Gemcitabine alone vs gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a federation nationale de Centres de Lutte Contre Le Cancer (FNCLCC) French Sarcoma Group (TAXOGEM) study.Google Scholar
  74. 74.
    Hadoux J, et al. Multimodal treatment with doxorubicin, cisplatin and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience. Int J Gynecol Cancer. 2015;25(2):296–302.PubMedGoogle Scholar
  75. 75.
    Sutton G, Blessing J, Hanjani P, Kramer P, Gynecologic Oncology Group. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;96:749–52.PubMedGoogle Scholar
  76. 76.
    Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1992;166:556–9.PubMedGoogle Scholar
  77. 77.
    Look KY, Sandler A, Blessing JA, et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2004;92:644–7.PubMedGoogle Scholar
  78. 78.
    Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480–90.PubMedGoogle Scholar
  79. 79.
    Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol. 2001;19:1248–55.PubMedGoogle Scholar
  80. 80.
    Thigpen T, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1991;9:1962–6.PubMedGoogle Scholar
  81. 81.
    McMeekin DS, et al. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gyn Oncology. 2007;106(3):596–603.Google Scholar
  82. 82.
    Duska LR, et al. A phase II evaluation of ixabepilone in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gyn Oncology. 2014;135:44–8.Google Scholar
  83. 83.
    Hensley ML, et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study. Gyn Oncology. 2009;115:460–5.Google Scholar
  84. 84.
    Gremel G, et al. A prognosis based classification of undifferentiated uterine sarcomas: identification of mitotic index, hormone receptors and YWHAE-FAM22 translocation status as predictors of survival. Int J Cancer. 2015;136(7):1608–18.PubMedGoogle Scholar
  85. 85.
    Lee CH, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high grade and clinically aggressive tumor. Am J Surg Pathol. 2012;36(5):641–53.PubMedGoogle Scholar
  86. 86.
    Lee CH, et al. Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol. 2012;36(10):1562–70.PubMedPubMedCentralGoogle Scholar
  87. 87.
    Malouf GG, et al. Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. Int J Gynecol Obset. 2013;122(1):57–61.Google Scholar
  88. 88.
    Tanner EJ, et al. High grade undifferentiated uterine sarcoma: surgery, treatment, and survival outcomes. Gynecol Oncol. 2012;127:27–31.PubMedGoogle Scholar
  89. 89.
    Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. Obstet Gynecol. 1996;87:747–50.PubMedGoogle Scholar
  90. 90.
    Lin YC, Kudelka AP, Tresukosol D, et al. Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy. Gyencol Oncol. 1995;58:262–5.Google Scholar
  91. 91.
    Takano T, et al. Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma in undifferentiated endometrial sarcoma in Japan. Int J Clin Oncol. 2014;19:897–905.PubMedGoogle Scholar
  92. 92.
    Kalender ME, et al. Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low grade endometrial stromal sarcoma. Cancer Chemother Parmacol. 2009;63(3):555–9.Google Scholar
  93. 93.
    Amant F, et al. Gynecologic Cancer InterGroup consensus review for endometrial stromal sarcoma. Int J Gynecol Cancer. 2014;24(9):S67–72.PubMedGoogle Scholar
  94. 94.
    Rauh-Hain JA, et al. Endometrial stromal sarcoma: a systematic review. Obstet Gynecol. 2013;122:676–83.PubMedGoogle Scholar
  95. 95.
    Tanz R, et al. Endometrial stromal sarcoma: prognostic factors and impact of adjuvant therapy in early stages. Hematol Oncol Stem Cell Ther. 2012;5(1):31–5.PubMedGoogle Scholar
  96. 96.
    Leitao MM, Soslow RA, Nonaka D, et al. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004;101:1455–62.PubMedGoogle Scholar
  97. 97.
    O’Cearbhaill R, et al. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol. 2010;116:424–9.PubMedGoogle Scholar
  98. 98.
    George et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014;120:738–43.Google Scholar
  99. 99.
    Mackay HJ, Buckanovich RJ, Hirte H, et al. A phase II study of single agent aflibercept (VEGF trap) in metastatic gynecologic carcinosarcomas and uterine leiomyosarcomas: a trial of the Princess Margaret Hospital, Chicago and Californai Cancer Consortia. Gynecol Oncol. 2012;125:136–40.PubMedGoogle Scholar
  100. 100.
    Cheng X, et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol. 2011;121:323–7.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Division of Gynecologic Oncology, Department of Obstetrics and GynecologyNYU School of MedicineNew YorkUSA

Personalised recommendations